Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Mtrr Rs1801394 and Its Interaction With Mthfr Rs1801133 in Colorectal Cancer: A Case-Control Study and Meta-Analysis Publisher Pubmed



Haerian MS1, 2 ; Haerian BS1 ; Molanaei S3 ; Kosari F4 ; Sabeti S5 ; Bidarizerehpoosh F5 ; Abdolali E6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Bone and Joint Reconstruction Research Center, Shafa Yahyaeian Orthopedics Hospital, Iran University of Medical Science, Tehran, Iran
  3. 3. Department of Pathology, Milad Hospital, Tehran, Iran
  4. 4. Department of Pathology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Pathology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  6. 6. Department of Pathology, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Pharmacogenomics Published:2017


Abstract

Aim: This study aims to evaluate the association between the MTRR rs1801394 alone or in interaction with the MTHFR rs1801133 and susceptibility to colorectal cancer (CRC) and its characteristics in Iranian population. Additionally, both a systematic review and meta-Analysis were performed to derive a more precise assessment of this association. Materials & methods: Genomic DNA of 2332 subjects was genotyped for rs1801394. These data were pooled with 17 eligible studies for meta-Analysis. Results: No significant association was found between the rs1801394 or rs1801394-rs1801133 and CRC risk. Meta-Analysis results also demonstrated no significant relationship between the rs1801394 and CRC risk. Conclusion: Results of this study showed that the rs1801394 alone or together with the rs1801133 is not a risk factor for CRC in Iranian population. © 2017 Future Medicine Ltd.